Table 3. Univariate and multivariate analysis of prognostic factors in HCC for overall survival.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | p > |z| | 95% CI | HR | p > |z| | 95% CI | |
| MAGE-A9 expression | ||||||
| High versus Low | 3.22 | 0.001* | 1.804–5.737 | 2.17 | 0.022* | 1.121–4.205 |
| Gender | ||||||
| Male versus Female | 1.13 | 0.740 | 0.554–2.297 | |||
| Age (years) | ||||||
| <60 versus ≥60 | 1.72 | 0.121 | 0.867–3.396 | |||
| Tumour size (cm) | ||||||
| >5 versus ≤5 | 1.84 | 0.031* | 1.058–3.183 | 1.44 | 0.244 | 0.778–2.679 |
| α-fetoprotein status | ||||||
| High versus Low | 1.03 | 0.896 | 0.618–1.734 | |||
| Hepatitis B virus infection | ||||||
| Positive versus Negative | 1.19 | 0.539 | 0.682–2.078 | |||
| Liver cirrhosis | ||||||
| Positive versus Negative | 0.84 | 0.519 | 0.494–1.428 | |||
| Pathological grade | ||||||
| Grade 1 and 2 versus Grade 3 | 0.44 | 0.005* | 0.245–0.783 | 0.79 | 0.455 | 0.425–1.467 |
| Portal vein invasion | ||||||
| Positive versus Negative | 3.33 | 0.001* | 1.966–5.645 | 1.95 | 0.039* | 1.035–3.656 |
| Lymph node metastasis | ||||||
| Positive versus Negative | 2.42 | 0.001* | 1.408–4.159 | 1.74 | 0.066 | 0.964–3.133 |
| Distant metastasis | ||||||
| Positive versus Negative | 2.10 | 0.088 | 0.896–4.917 | |||
| TNM stage | ||||||
| Stage I-II versus Stage III-IV | 0.35 | 0.001* | 0.200–0.612 | 0.86 | 0.690 | 0.411–1.800 |
| MAGE-A9 expression + α-fetoprotein status | ||||||
| Both high versus Others situations (High + Low or Low + High or Both low) | 1.59 | 0.100 | 0.915–2.748 | |||
*p < 0.05.